N4 Pharma Plc

N4 Pharma Plc is a drug reformulation company focused on developing and out licensing new versions of existing and novel high value drugs with an unmet commercial or medical need. The company's commercial strategy involves advancing a pipeline of products through clinical proof of concept and then partnering to take the products through the relevant regulatory pathway studies to regulatory approval. Recently, N4 Pharma acquired the rights to a range of patents from OPAL IP to allow it to reformulate a wide range of existing drugs using a range of techniques. Additionally, the company has two proprietary platform delivery system technologies that enable it to improve a vaccine's performance. The first system enhances cellular uptake of sub unit vaccines, while the second improves transfection efficiency of cancer vaccines and therapeutics. Founded in 2014 and headquartered in the United Kingdom, N4 Pharma's first product in development is a 'reformulated' version of Sildenafil (Viagra) aimed at improving the onset of action and maintaining an effective dose of the drug during the therapeutic window to make it last longer. In terms of investment, N4 Pharma's last investment was a £119.00K grant investment received on January 5, 2017, with Innovate UK as the investor.